Literature DB >> 19422879

Regulation of AKR1B1 by thyroid hormone and its receptors.

Chen-Shin Liao1, Pei-Ju Tai, Ya-Hui Huang, Ruey-Nan Chen, Sheng-Ming Wu, Lu-Wei Kuo, Chau-Ting Yeh, Ming-Ming Tsai, Wei-Jan Chen, Kwang-Huei Lin.   

Abstract

The objective of this study was to identify genes regulated by thyroid hormone (T(3)) mediated by its receptor (TR) and associated with tumorigenesis. The gene encoding aldo-keto reductase family 1, member B1 (AKR1B1), as previously identified by c-DNA microarray, is known to be up-regulated by T(3) treatment. Enzyme AKR1B1 was elevated roughly 3-fold in HepG2-TRalpha1 cells at the protein level and 4.6-fold increase at the mRNA level after 48 h T(3) treatment. Similar findings were obtained from thyroidectomized rats after T(3) application. To identify and localize the critical TR element (TRE), series deletion of the promoter mutant were constructed and electrophoretic mobility shift assays were carried out. The TRE on the AKR1B1 promoter was localized to the -1099/-1028 region. Further, this study demonstrated that AKR1B1 over-expression in some types of hepatocellular carcinomas (HCCs) is TR-dependent and might play a crucial role in the development of HCC. Thus, T(3) regulates AKR1B1 gene expression via a TRE-dependant mechanism and associates liver cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19422879     DOI: 10.1016/j.mce.2009.04.013

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  7 in total

Review 1.  Thyroid hormone actions in liver cancer.

Authors:  Sheng-Ming Wu; Wan-Li Cheng; Crystal D Lin; Kwang-Huei Lin
Journal:  Cell Mol Life Sci       Date:  2012-09-06       Impact factor: 9.261

2.  Regulation of aldo-keto reductases in human diseases.

Authors:  Wei-Dong Chen; Yanqiao Zhang
Journal:  Front Pharmacol       Date:  2012-03-09       Impact factor: 5.810

Review 3.  Thyroid Hormone in Hepatocellular Carcinoma: Cancer Risk, Growth Regulation, and Anticancer Drug Resistance.

Authors:  Yang-Hsiang Lin; Kwang-Huei Lin; Chau-Ting Yeh
Journal:  Front Med (Lausanne)       Date:  2020-05-22

Review 4.  Role of aldo-keto reductase family 1 member B1 (AKR1B1) in the cancer process and its therapeutic potential.

Authors:  Reza Khayami; Seyyed Reza Hashemi; Mohammad Amin Kerachian
Journal:  J Cell Mol Med       Date:  2020-07-06       Impact factor: 5.310

Review 5.  Molecular functions of thyroid hormones and their clinical significance in liver-related diseases.

Authors:  Hsiang Cheng Chi; Cheng-Yi Chen; Ming-Ming Tsai; Chung-Ying Tsai; Kwang-Huei Lin
Journal:  Biomed Res Int       Date:  2013-06-26       Impact factor: 3.411

6.  Chemotherapy resistance and metastasis-promoting effects of thyroid hormone in hepatocarcinoma cells are mediated by suppression of FoxO1 and Bim pathway.

Authors:  Hsiang-Cheng Chi; Shen-Liang Chen; Yi-Hung Cheng; Tzu-Kang Lin; Chung-Ying Tsai; Ming-Ming Tsai; Yang-Hsiang Lin; Ya-Hui Huang; Kwang-Huei Lin
Journal:  Cell Death Dis       Date:  2016-08-04       Impact factor: 8.469

7.  Quantitative proteomic analysis reveals that Luks-PV exerts antitumor activity by regulating the key proteins and metabolic pathways in HepG2 cells.

Authors:  Chang-Cheng Zhao; Wen-Wei Yu; Ying-Jie Qi; Liang-Fei Xu; Zi-Ran Wang; Ya-Wen Qiang; Fan Ma; Xiao-Ling Ma
Journal:  Anticancer Drugs       Date:  2020-03       Impact factor: 2.389

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.